Home » Stocks » DBVT

DBV Technologies S.A. (DBVT)

Stock Price: $6.04 USD -0.21 (-3.36%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 683.77M
Revenue (ttm) 13.75M
Net Income (ttm) -194.58M
Shares Out 109.75M
EPS (ttm) -1.48
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $6.04
Previous Close $6.25
Change ($) -0.21
Change (%) -3.36%
Day's Open 6.17
Day's Range 6.02 - 6.20
Day's Volume 67,607
52-Week Range 1.35 - 7.38

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Montrouge, France, April 2, 2021 DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors

2 weeks ago - GlobeNewsWire

Monthly information regarding the total number of voting rights and

2 weeks ago - GlobeNewsWire

Monthly information regarding the total number of voting rights and

1 month ago - GlobeNewsWire

The company released its latest quarterly update, and investors liked what they saw.

1 month ago - The Motley Fool

Montrouge, France, March 11, 2021

1 month ago - GlobeNewsWire

Montrouge, France, March 5, 2021

1 month ago - GlobeNewsWire

Montrouge, France, March 3, 2021

1 month ago - GlobeNewsWire

Montrouge, France, March 1, 2020

1 month ago - GlobeNewsWire

Montrouge, France, February 24, 2021

1 month ago - GlobeNewsWire

Montrouge, France, February 22, 2021

1 month ago - GlobeNewsWire

Montrouge, France, February 19, 2021

2 months ago - GlobeNewsWire

Monthly information regarding the total number of voting rights and

2 months ago - GlobeNewsWire

AMF REGULATED INFORMATION Montrouge, France, January 29, 2021

2 months ago - GlobeNewsWire

After hitting a major regulatory roadblock, DBV Technologies sees a path to approval for its leading candidate.

3 months ago - The Motley Fool

DBV Technologies (DBVT) stock is soaring higher on Friday after providing an update on its upcoming peanut allergy treatment. The post DBVT Stock: DBV Technologies Soars on Big Peanut Allergy Patch News...

3 months ago - InvestorPlace

Monthly information regarding the total number of voting rights and

3 months ago - GlobeNewsWire

Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2020

4 months ago - GlobeNewsWire

Montrouge, France, November 24, 2020

4 months ago - GlobeNewsWire

Monthly information regarding the total number of voting rights and 

5 months ago - GlobeNewsWire

Montrouge, France, November 10, 2020 DBV Technologies to Highlight Data on Viaskin ™ Peanut Treatment Delivery and Patient Experience at ACAAI 2020

5 months ago - GlobeNewsWire

Montrouge, France, November 9, 2020 DBV Technologies to Participate in Upcoming Investor Conferences

5 months ago - GlobeNewsWire

The company submitted its potential peanut allergy treatment for review in Europe.

5 months ago - The Motley Fool

DBV Technologies S.A. (NASDAQ: DBVT) shares absolutely exploded on Monday after the firm announced that the Marketing Authorization Application (MAA) for its peanut allergy treatment was validated by th...

5 months ago - 24/7 Wall Street

Montrouge, France, October 30, 2020

5 months ago - GlobeNewsWire

Monthly information regarding the total number of voting rights and

6 months ago - GlobeNewsWire

Monthly information regarding the total number of voting rights and 

7 months ago - GlobeNewsWire

Montrouge, France, September 2, 2020

7 months ago - GlobeNewsWire

Monthly information regarding the total number of voting rights and 

8 months ago - GlobeNewsWire

Shares of DBV Technologies tumbled 8.5% in premarket trading on Wednesday, the day after the company said it had received a complete response letter from the Food and Drug Administration for its experi...

8 months ago - Market Watch

ATLANTA--(BUSINESS WIRE)--Holzer & Holzer, LLC is investigating whether DBV Technologies S.A. (“DBV Technologies” or the “Company”) (NASDAQ: DBVT) complied with federal securities laws.

8 months ago - Business Wire

The FDA rejected the company’s application for its peanut-allergy patch.

8 months ago - The Motley Fool

Montrouge, France, July 31, 2020

8 months ago - GlobeNewsWire

Montrouge, France, July 20, 2020

8 months ago - GlobeNewsWire

Monthly information regarding the total number of voting rights and 

9 months ago - GlobeNewsWire

The company provided a grim business update.

9 months ago - The Motley Fool

Montrouge, France, June 26, 2020

9 months ago - GlobeNewsWire

Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2020

10 months ago - GlobeNewsWire

Montrouge, France, June 2, 2020

10 months ago - GlobeNewsWire

Information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2020

11 months ago - GlobeNewsWire

Aimmune Therapeutics Beats DBV Technologies In Multi-Billion Dollar Market To Treat Peanut Allergies

Other stocks mentioned: AIMT
11 months ago - Seeking Alpha

Montrouge, France, April 30, 2020

11 months ago - GlobeNewsWire

Montrouge, France, April 20, 2020

11 months ago - GlobeNewsWire

About DBVT

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosi... [Read more...]

Industry
Biotechnology
Founded
2002
CEO
Daniel Tasse
Employees
141
Stock Exchange
NASDAQ
Ticker Symbol
DBVT
Full Company Profile

Financial Performance

In 2020, DBVT's revenue was 11.28 million, a decrease of -23.33% compared to the previous year's 14.71 million. Losses were -159.56 million, -7.24% less than in 2019.

Financial numbers in millions EUR.
Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for DBVT stock is "Buy." The 12-month stock price forecast is 9.67, which is an increase of 60.10% from the latest price.

Price Target
$9.67
(60.10% upside)
Analyst Consensus: Buy